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Original Article

Adjuvant Chemotherapy plus Radiation
for Locally Advanced Endometrial Cancer
Daniela Matei, M.D., Virginia Filiaci, Ph.D., Marcus E. Randall, M.D.,
David Mutch, M.D., Margaret M. Steinhoff, M.D., Paul A. DiSilvestro, M.D.,
Katherine M. Moxley, M.D., Yong M. Kim, M.D., Ph.D., Matthew A. Powell, M.D.,
David M. O’Malley, M.D., Nick M. Spirtos, M.D., William Small, Jr., M.D.,
Krishnansu S. Tewari, M.D., William E. Richards, M.D., John Nakayama, M.D.,
Ursula A. Matulonis, M.D., Helen Q. Huang, M.S., and David S. Miller, M.D.

A BS T R AC T
BACKGROUND

Stage III or IVA endometrial cancer carries a significant risk of systemic and loco
regional recurrence.
METHODS

In this randomized phase 3 trial, we tested whether 6 months of platinum-based
chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer
relapse-free survival (primary end point) than six cycles of combination chemo
therapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end
points included overall survival, acute and chronic toxic effects, and quality of life.
RESULTS

Of the 813 patients enrolled, 736 were eligible and were included in the analysis
of relapse-free survival; of those patients, 707 received the randomly assigned in
tervention (346 received chemoradiotherapy and 361 received chemotherapy only).
The median follow-up period was 47 months. At 60 months, the Kaplan–Meier
estimate of the percentage of patients alive and relapse-free was 59% (95% confi
dence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI,
53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to
1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal
recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and
paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28
to 0.66) than chemotherapy alone, but distant recurrence was more common in
association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00
to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the
chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group.
CONCLUSIONS

Chemotherapy plus radiation was not associated with longer relapse-free survival
than chemotherapy alone in patients with stage III or IVA endometrial carcinoma.
(Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.)
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omen with locally advanced (International Federation of Gynecology
and Obstetrics [FIGO] stage III or IVA)
endometrial carcinoma are a heterogeneous group
of patients who are at risk for both local and
systemic disease recurrence. Clinical and patho
logic factors affecting the risk of recurrence in
clude the extent of abdominal and pelvic disease,
histologic subtype, nodal involvement, presence
of extranodal disease, and the completeness of
surgical resection.1-4 Because of the heterogeneity
of this patient population, a wide range of 5-year
survival estimates has been reported, and an ap
propriate postsurgery strategy remains unclear.5-8
Pelvic or whole abdominal radiotherapy has
traditionally followed surgical resection.6,8 This
approach prevented pelvic recurrence but was
less effective in preventing systemic recurrence,
which limited long-term survival. In a randomized
trial conducted by the Gynecologic Oncology
Group (GOG), GOG 122, chemotherapy was found
to be superior to radiotherapy in treating locally
advanced disease, and it thus became part of the
standard treatment.9 However, if chemotherapy
is given alone, the incidence of locoregional re
currence approaches 20%,9 heralding subsequent
distant metastasis and death. Therefore, it was
logical to hypothesize that an approach that com
bined the methods of treatment would improve
outcomes by preventing local (pelvic) and distant
recurrences.
This combined approach has been studied,
but its efficacy relative to that of chemotherapy
alone is not known. Patients with stage III endo
metrial carcinoma treated with chemoradiother
apy in the Radiation Therapy Oncology Group
(RTOG) protocol 9708 trial had an estimated
4-year overall survival of 77% and relapse-free
survival of 72%.10 In the GOG 184 trial, which
compared two chemotherapy regimens after tu
mor volume–directed external-beam radiotherapy,
the 3-year relapse-free survival estimates were
62% to 64%.11 These results supported the fea
sibility and efficacy of a combined treatment
strategy.
The purpose of the current trial (GOG 258)
was to evaluate the use of concurrent tumor
volume–directed external-beam radiation ther
apy and chemotherapy (i.e., chemoradiotherapy)
as compared with the use of chemotherapy
alone.9,11-13 Here, we report on relapse-free sur
vival, the primary end point.
2318
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Me thods
Patients and Trial Oversight

We enrolled women who were 18 years of age or
older and who had surgical stage III or IVA en
dometrial carcinoma according to FIGO 2009
staging criteria of any histologic subtype or had
FIGO 2009 surgical stage I or II clear-cell or
serous endometrial carcinoma and peritoneal
washings that were positive for cancer cells.
Hysterectomy and bilateral salpingo-oophorec
tomy had to have been performed within 8 weeks
before trial entry. No single residual tumor mass
could be larger than 2 cm in greatest dimension.
Pelvic and paraaortic lymph-node biopsy or dis
section was optional. Normal organ function
and a GOG performance status score of 2 or
lower were required (scores range from 0 to 5,
with higher scores reflecting greater disability).
Patients with carcinosarcoma or recurrent endo
metrial carcinoma were excluded.
The trial was conducted in accordance with
applicable regulatory requirements and the prin
ciples of the Declaration of Helsinki. Approval for
the trial and for the informed-consent process
from a local or central institutional review board
or independent ethics committee was required
for site participation. Patients provided written
informed consent before enrollment.
Trial Design and End Points

This randomized, multicenter, phase 3 trial was
designed with input from the Gynecologic Oncol
ogy Group. The authors vouch for the accuracy
and completeness of the data and for the fidelity
of the trial to the protocol, available with the
full text of this article at NEJM.org. The trial
treatments were paid for by medical insurance,
and the trial was supported by the National Can
cer Institute. All the patients were registered
through the National Cancer Institute Oncology
Patient Enrollment Network. Treatment was ran
domly assigned at the GOG Statistical and Data
Center and was concealed until registration with
verification of eligibility. Randomization was
stratified according to age and the presence or
absence of gross residual disease. The primary
objective was to determine whether chemoradio
therapy would be associated with a lower incidence
of recurrence or death (i.e., longer relapse-free
survival) than chemotherapy alone. Secondary ob
jectives were between-group comparisons of over
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all survival, the incidence and severity of acute much). The total FACT-En Trial Outcome Index
and late toxic effects, and patient-reported qual score was calculated as the sum of the subscale
ity of life.
scores if more than 80% of the items were an
swered within each subscale. The total scores
Treatment and Assessments
range from 0 to 120 for the FACT-En Trial Outcome
The two treatment regimens were randomly as Index and from 0 to 16 for the FACT/GOG-NTX
signed in a 1:1 ratio within permuted blocks. subscale (see the Supplementary Appendix). A
The chemoradiotherapy regimen consisted of cis higher Trial Outcome Index, NTX, or gastrointes
platin at a dose of 50 mg per square meter of tinal score suggests better quality of life or fewer
body-surface area given intravenously on days 1 and symptoms. The minimally clinically important dif
29 together with volume-directed external-beam ference is 6 points for the FACT-En Trial Outcome
radiation therapy, followed by carboplatin given Index and 1.2 points for the FACT/GOG-NTX
at a dose to achieve an area under the concentra subscale.14 Assessments were completed before
tion–time curve (AUC) of 5 to 6 plus paclitaxel at treatment (at baseline), 1 week after completing
a dose of 175 mg per square meter every 21 days radiation therapy or before cycle 3 of chemo
for four cycles, with granulocyte colony-stimu therapy, and 18 and 70 weeks after the start of
lating factor (G-CSF) support. The chemotherapy- treatment.
only regimen consisted of carboplatin (to achieve
an AUC of 6) plus paclitaxel at a dose of 175 mg Quality Assurance
per square meter every 21 days for six cycles. In The trial was open to enrollment between June
the chemoradiotherapy group, external-beam ra 29, 2009, and July 28, 2014, and the data cutoff
diation therapy was delivered to the pelvis with for analysis was March 9, 2017. The GOG Pathol
or without paraaortic fields. The planned total ogy Committee verified histologic subtypes, grades,
dose was 4500 cGy in 25 fractions at 180 cGy per and stages for all patients. Eligibility, surgery,
fraction. Intensity-modulated radiotherapy and and radiation plans were reviewed centrally. The
vaginal brachytherapy were allowed only in the trial chairs monitored eligibility, chemotherapy
chemoradiotherapy group. Disease assessments delivery and modifications, adverse events, and
included computed tomography (CT) of the ab radiographic assessments.
domen and pelvis and chest radiography at base
line, the end of treatment, every 6 months for Statistical Analysis
the first 2 years, and then annually up to 5 years. The null hypothesis was that chemoradiotherapy
Safety assessments included recording of adverse would not achieve higher relapse-free survival
events and concomitant medications, physical ex percentages than chemotherapy alone. A 28.5%
amination, and hematologic and chemical testing lower incidence of recurrence or death (relative
on the same schedule. Adverse events were grad hazard, 1.4, corresponding to relapse-free sur
ed with the use of the Common Terminology vival at 3 years of 61% in the chemotherapy-only
Criteria for Adverse Events (CTCAE), version 3.0. group and 70% in the chemoradiotherapy group)
Annual follow-up was planned beyond 5 years. was considered clinically significant. Observation
The Trial Outcome Index of the Functional of at least 252 recurrences or death events was
Assessment of Cancer Therapy (FACT) for endo needed to attain 85% statistical power with type I
metrial cancer (FACT-En) and the FACT/GOG– error for a one-tailed comparison at 0.05 for
neurotoxicity (NTX) subscale were used to mea relapse-free and overall survival separately. Under
sure quality of life and chemotherapy-induced the assumption of a decrease in the hazard of
neurotoxic effects (see the Supplementary Appen recurrence or death over time, a sample size of
dix, available at NEJM.org). Two items from the 804 was targeted. Independence between relapseFACT for colorectal cancer (FACT-C) combined free or overall survival and the randomly assigned
with four items from the FACT-En Trial Outcome treatment was assessed with a stratified log-rank
Index were used to assess gastrointestinal symp test in an intention-to-treat analysis including
toms. Each item in the FACT-En Trial Outcome the eligible patients. Two interim analyses were
Index and the FACT/GOG-NTX subscale was planned when 42% (105) and 83% (210) of the
scored with the use of a 5-point scale (0, not at all; expected number of recurrences or deaths had
1, a little bit; 2, somewhat; 3, quite a bit; 4, very been reported. These were reported to the data
n engl j med 380;24
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Table 1. Characteristics of the Patients.*

Characteristic

Chemoradiotherapy
(N = 370)

Chemotherapy
Only
(N = 366)

60.5 (31–88)

60 (31–85)
279 (76.2)

Mean age (range) — yr
Race — no. (%)†
White

291 (78.6)

Black

37 (10.0)

42 (11.5)

Asian, other, or not specified

42 (11.4)

45 (12.3)

0

278 (75.1)

268 (73.2)

1

88 (23.8)

96 (26.2)

2

4 (1.1)

2 (0.5)

GOG performance status score — no. (%)‡

FIGO stage — no. (%)§
6 (1.6)

10 (2.7)

IIIA

I or II

70 (18.9)

81 (22.1)

IIIB

12 (3.2)

13 (3.6)

IIIC1

189 (51.1)

166 (45.4)

IIIC2

90 (24.3)

93 (25.4)

IVA

3 (0.8)

3 (0.8)

Endometrioid, grade 1

87 (23.5)

79 (21.6)
118 (32.2)

Histology and grade — no. (%)
Endometrioid, grade 2

103 (27.8)

Endometrioid, grade 3

64 (17.3)

61 (16.7)

Serous

66 (17.8)

65 (17.8)

Clear cell

10 (2.7)

12 (3.3)

Mixed epithelial or other

40 (10.8)

31 (8.5)

Absent

360 (97.3)

359 (98.1)

Present

10 (2.7)

7 (1.9)

32.0 (11.2–65.3)

32.9 (18–60.2)

72 (19.5)

71 (19.4)

Gross residual disease — no. (%)

Median BMI (range)¶
BMI category — no. (%)
Normal or underweight
Overweight
Obesity class I, II, or III

84 (22.7)

81 (22.1)

214 (57.8)

214 (58.5)

*	There were no significant differences in baseline characteristics between the
treatment groups. Percentages may not total 100 because of rounding.
†	Race was reported by the patient.
‡	A Gynecologic Oncology Group (GOG) performance status score of 2 or lower
was required for enrollment (scores range from 0 to 5, with higher scores reflecting greater disability).
§	Stages were assigned according to the International Federation of Gynecology
and Obstetrics (FIGO) 2009 classification; stages range from I to IV, with higher
stages indicating more advanced spread of cancer.
¶	Body-mass index (BMI) is the weight in kilograms divided by the square of the
height in meters.
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interim analyses. A Kruskal–Wallis test correct
ed for ties was used to compare the maximum
grade of acute and late adverse effects of therapy
(see the Supplementary Appendix). Betweengroup differences in quality-of-life scores were
assessed with a linear mixed model with adjust
ment for the pretreatment score, assessment
time point, and age at enrollment.

R e sult s
Patients and Follow-up

Enrollment concluded with 813 patients; 77 were
deemed ineligible, most commonly because of
an inappropriate cancer stage or a lack of patho
logical documentation. In addition, 29 eligible
patients were never treated, with 24 of those hav
ing been assigned to the chemoradiotherapy group.
At the time of this report, all patients were no
longer receiving the trial treatment and, after treat
ment, 25 women had withdrawn consent for con
tinued follow-up (12 in the chemoradiotherapy
group and 13 in the chemotherapy-only group)
(Fig. S1 in the Supplementary Appendix). There
were 51 major protocol violations in 399 reviewed
cases: 43 in the chemoradiotherapy group and 8 in
the chemotherapy-only group; 15 in the chemo
radiotherapy group were related to radiation de
livery (see the Supplementary Appendix).
The median follow-up duration was 47 months;
295 recurrence or death events were reported in
the entire study population, and 271 were report
ed among eligible patients. The safety analysis in
cluded all eligible and treated patients, whereas
the efficacy analysis included all eligible patients,
regardless of whether they received treatment.
Characteristics of the patient and the tumors
are shown in Table 1. A total of 72% of patients
were between 50 and 69 years of age (median age,
60 years), 90% identified as non-Hispanic, and
77% identified as white. The performance status
score was 0 for 74% of enrolled patients, and the
endometrioid histologic type was predominant.
Stratification factors were balanced between the
treatment groups, with nearly 98% of patients
having no gross residual disease. Surgery to re
move lymph nodes was reported in more than
94% of patients, with a median number of 13
pelvic nodes and 3 paraaortic nodes removed.

and safety monitoring board in September 2013 Treatment
and January 2016. No action was taken to alter Overall, 75% of patients completed all prescribed
the conduct of the trial on the basis of those chemoradiotherapy in a median period of 21 weeks.
2320
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Table 2. Acute Adverse Events.
Adverse Event

Chemoradiotherapy (N = 346)

Chemotherapy Only (N = 361)

Any Grade

Grade 3–5

Any Grade

P Value*

Constitutional symptom

87

6

80

2

0.004

Fatigue

85

5

75

2

<0.001

Cardiac event

16

3

19

4

0.71

Endocrine event

11

1

11

0

0.46

Gastrointestinal event

90

13

79

4

<0.001

Renal or genitourinary event

33

2

11

1

<0.001

Blood or bone marrow event

96

40

90

52

0.01

Infection

23

4

20

5

0.18

Lymphatic event

17

<1

16

<1

0.74

Musculoskeletal event

20

3

13

1

0.01

Metabolic or laboratory event

48

15

44

9

0.02

Neurologic event

76

7

80

5

0.99

Grade 3–5

percent of patients

Pulmonary event

31

2

26

1

0.83

Pain

70

8

68

5

0.04

*	P values for the between-group comparison of the maximum grade of adverse events were calculated with a Kruskal–
Wallis test corrected for ties.

The majority of patients in the chemoradiother
apy group received 45 cGy, intensity-modulated
radiotherapy was used in 30% of cases, and 201
patients received vaginal-cuff brachytherapy. Two
cycles of cisplatin were coadministered with radia
tion to more than 85% of patients in the chemo
radiotherapy group, and 75% of the patients in
that group received all four planned cycles of
carboplatin and paclitaxel. In the chemotherapyonly group, 85% of women received all six cycles
during a median period of 17 weeks (Table S1 in
the Supplementary Appendix). Two patients in the
chemotherapy-only group received additional che
motherapy and radiotherapy before progression;
both patients discontinued the trial treatment
early because of toxic effects. Between 8 and
10% of patients discontinued treatment due to
adverse events.

therapy group and in 108 patients (30%) in the
chemotherapy-only group. Two deaths were attrib
uted to the trial treatment; both deaths occurred
in the chemotherapy-only group (grade 5 sepsis
and sudden death). Constitutional symptoms,
fatigue, gastrointestinal events, renal or genito
urinary events, and musculoskeletal events were
significantly more frequent per grade in the
chemoradiotherapy group. Hematologic adverse
events were significantly more frequent and more
severe in the chemotherapy-only group. Late toxic
effects are summarized in Table S2 in the Sup
plementary Appendix. A grade 4 or higher late
adverse event was reported in 15 patients in the
chemoradiotherapy group and in 11 patients in
the chemotherapy-only group. No deaths that were
determined by the trial chairs to be attributable to
treatment occurred during the follow-up period.

Toxicity

Efficacy

Table 2 shows acute adverse events, regardless
of attribution to the trial intervention, in the 707
eligible participants who initiated treatment.
Grade 3, 4, or 5 adverse events were reported in
202 patients (58%) in the chemoradiotherapy
group and 227 patients (63%) in the chemotherapyonly group. A grade 4 or higher acute adverse event
occurred in 48 patients (14%) in the chemoradio

The results with regard to the primary end point
did not reach significance. At 60 months, the
Kaplan–Meier estimate of the percentage of pa
tients who were alive and recurrence-free was
59% (95% confidence interval [CI], 53 to 65) in
the chemoradiotherapy group and 58% (95% CI,
53 to 64) in the chemotherapy-only group (haz
ard ratio, 0.90; 90% Wald CI, 0.74 to 1.10).
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Proportion Alive and Recurrence-free

0.9
Chemoradiotherapy

0.7
0.6

Chemotherapy only

0.5
0.4

Chemoradiotherapy
Chemotherapy Only

0.3
0.2

Total
No.
370
366

Hazard ratio, 0.90 (90% CI, 0.74–1.10)
P=0.20

0.1
0.0

No. of
Events
132
139

0

12

24

36

Quality of Life

48

60

72

103
113

45
55

19
17

Months
No. at Risk
Chemoradiotherapy
Chemotherapy only

370
366

295
293

235
230

164
159

Figure 1. Relapse-free Survival.
Tick marks indicate censored data.

Therefore, the null hypothesis that chemoradio
therapy is not superior to chemotherapy alone
could not be rejected (P = 0.20 by one-tailed test)
(Fig. 1). A sensitivity analysis indicated that the
results observed in the eligible treated popula
tion were consistent with the results among all
eligible patients.
A total of 165 deaths have been reported to
date — 86 in the chemoradiotherapy group and
79 in the chemotherapy-only group. Of those
deaths, 73% and 81%, respectively, were due to
endometrial cancer progression. The data on over
all survival are not sufficiently mature to allow
comparison between the groups. Exploratory sub
group analyses of relapse-free survival did not
identify a subgroup of patients who may have
benefited more from chemoradiotherapy than
from chemotherapy alone, when age, histologic
subtype, surgical stage, body-mass index, and
the presence or absence of gross residual disease
were taken into consideration (Fig. 2). The cumu
lative incidence of vaginal disease recurrence at
60 months of follow-up was 2% in the chemora
diotherapy group and 7% in the chemotherapyonly group (hazard ratio, 0.36; 95% CI, 0.16 to
0.82) (Fig. 3A). The cumulative incidence of pel
vic or paraaortic node recurrence at 60 months
was 11% in the chemoradiotherapy group and
20% in the chemotherapy-only group (hazard
ratio, 0.43; 95% CI, 0.28 to 0.66) (Fig. 3B). The
2322
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cumulative incidence of distant recurrence at
60 months was 27% in the chemoradiotherapy
group and 21% in the chemotherapy-only group
(hazard ratio, 1.36; 95% CI, 1.00 to 1.86)
(Fig. 3C). Coincident local and distant recur
rences at first presentation were found in 2.2%
of patients in the chemoradiotherapy group and
in 4.9% of patients in the chemotherapy-only
group; the sites of initial recurrence are shown
in Table S3 in the Supplementary Appendix.

1.0

0.8

of

n engl j med 380;24

Adherence to the quality-of-life assessments was
95% at baseline, 90% at 6 weeks, 87% at 18
weeks, and 78% at 70 weeks. The patients who
could be evaluated were those with a valid base
line assessment and at least one follow-up assess
ment (332 in the chemoradiotherapy group and
349 in the chemotherapy-only group). After ad
justment for age and baseline scores, the leastsquares mean Trial Outcome Index score at 18
weeks in the chemoradiotherapy group was 5.2
points lower (97.5% CI, 2.7 to 7.8) than that in
the chemotherapy-only group. The difference in
this score remained significant at 70 weeks (3.4
points lower in the chemoradiotherapy group;
97.5% CI, 0.7 to 6.2) but did not exceed the
6-point difference that had been preset as clini
cally meaningful.14 Patients in both groups re
ported symptoms of neurotoxicity in associa
tion with treatment, but the least-squares mean
FACT/GOG-NTX subscale score at 6 weeks among
patients receiving chemotherapy only was 2.0
points lower (97.5% CI, 1.4 to 2.6) than that in
the chemoradiotherapy group (i.e., reflecting worse
symptoms in the chemotherapy-only group),
whereas patients receiving chemoradiotherapy re
ported gastrointestinal symptoms at both 6 weeks
and 18 weeks that were significantly worse than
those in the chemotherapy-only group.

Discussion
The role of radiotherapy in local control of endo
metrial carcinoma has been firmly established15-18;
however, external-beam radiotherapy does not
significantly improve overall survival in patients
with early-stage, lower-risk disease. This was
shown in both the Post Operative Radiation
Therapy in Endometrial Carcinoma (PORTEC) 1
trial and the GOG 99 trial,17,19 and its use in this
context remains tailored to women who are con

nejm.org

June 13, 2019

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 24, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

Chemother apy plus R adiation for Endometrial Cancer

Subgroup
FIGO stage
I, II, or IIIA
IIIB
IIIC or IIIC1
IIIC2 or IVA
Age at entry
≤65 yr
>65 yr
Gross residual disease
Absent
Present
Histology
Endometrioid, grade 1
Endometrioid, grade 2
Endometrioid, grade 3
Serous
Other
BMI category
Normal or underweight
Overweight
Obesity class I, II, or III
Primary analysis population

No. of
Events

Total
No.

52
15
113
91

167
25
355
189

0.76 (0.43–1.32)
1.65 (0.59–4.65)
1.21 (0.83–1.76)
0.73 (0.48–1.10)

165
106

532
204

0.98 (0.72–1.33)
0.81 (0.55–1.19)

260
11

719
17

0.93 (0.73–1.19)
0.81 (0.23–2.87)

32
67
48
74
50

166
221
129
131
89

0.98 (0.49–1.96)
1.05 (0.65–1.70)
1.09 (0.62–1.92)
0.85 (0.54–1.34)
0.68 (0.39–1.19)

53
74
144
271

143
165
428
736

1.09 (0.64–1.87)
0.92 (0.58–1.45)
0.92 (0.67–1.28)
0.90 (0.71–1.15)

Hazard Ratio (95% CI)

0.5
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Figure 2. Subgroup Analysis According to Recognized Prognostic Factors.
Stages were assigned according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification; stages range
from I to IV, with higher stages indicating more advanced spread of cancer. BMI denotes body-mass index.

sidered to be at high risk for relapse.20 Because
the risk of local relapse is higher among women
with stage III uterine cancer than among those
with early-stage disease,21 whole abdominal or
pelvic radiotherapy has traditionally been incor
porated in the standard postoperative approach
for those with stage III disease.6,22 However, given
the competing risk of distant metastasis, which
has led to the implementation of chemotherapy
as the standard of care,9 the role of radiotherapy
remains uncertain. This trial prospectively eval
uated the effect of combined chemotherapy plus
radiotherapy in patients with stage III or IVA
endometrial carcinoma as compared with the
effect of chemotherapy alone. The results show
that the combined regimen was not superior to
chemotherapy alone in prolonging relapse-free
survival, although locoregional relapses were less
frequent than with chemotherapy alone.
An important strength of this trial is the rig
orous definition of the patient population, which
includes only patients with adnexal, lymph-node,
n engl j med 380;24

and pelvic, nonperitoneal metastasis. With the
revision of the FIGO staging system in 2009,23
the trial was amended to exclude patients with
peritoneal washings that were positive for cancer
cells but with no evidence of extrauterine endo
metrioid tumor, because such patients have bet
ter outcomes than other patients with stage III
disease.24,25 One exception was the group of pa
tients with positive peritoneal washings and car
cinoma of the clear-cell or serous histologic type,
who are recognized as having a high risk of re
currence26-30; these patients were included in this
trial and represented less than 3% of the trial
population. Nearly 75% of the patient population
had endometrial carcinoma with lymph-node in
volvement. Although surgical staging was not
mandated, the majority of patients underwent
full staging procedures.
Chemotherapy became the mainstay of treat
ment for high-risk endometrial carcinoma after
it became clear that distant metastasis is a key
determinant of survival in patients with locally
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Figure 3 (facing page). Cumulative Risk of Recurrence.
The insets show the same data on an enlarged y axis.

advanced endometrial carcinoma. In the GOG
122 trial, overall survival at 60 months was 10 per
centage points higher among patients who received
doxorubicin and platinum than among those
treated with whole abdominal radiotherapy.9 The
role of chemotherapy has been studied by other
groups.5,31-33 Maggi et al. reported no significant
difference in overall survival between patients
who received cyclophosphamide, doxorubicin, and
cisplatin (CAP) and those who received externalbeam radiotherapy.31 In the Japanese Gyneco
logic Oncology Group trial, which involved pa
tients with high-risk endometrial carcinoma, the
percentages of patients surviving without pro
gression (83% vs. 66%) and surviving overall
(89% vs. 73%) were significantly higher among
those who were randomly assigned to receive
CAP than among those who received pelvic exter
nal-beam radiotherapy.32 In a pooled analysis of
trials conducted by the Nordic Society of Gyne
cological Oncology (NSGO)–European Organi
zation for Research and Treatment of Cancer
(EORTC) and the Mario Negri Gynecologic On
cology (MaNGO) group, sequential chemotherapy
and pelvic external-beam radiotherapy approached
statistical superiority to pelvic radiotherapy alone
(hazard ratio, 0.69; P = 0.07).33 Adjuvant chemo
radiotherapy was compared with external-beam
radiotherapy in patients with early-stage highrisk and stage III endometrial carcinoma in the
recently reported PORTEC 3 trial. Overall sur
vival was not affected by the addition of chemo
therapy, but the combined regimen improved
relapse-free survival relative to radiotherapy (75%
vs. 68%), with most of the benefit found in pa
tients with stage III disease.34
Several regimens have been tested in patients
with locally advanced or metastatic endometrial
carcinoma, including those regimens named
above, paclitaxel–doxorubicin–cisplatin, and carbo
platin–paclitaxel.11,13,31,33,35 Because carboplatin–
paclitaxel induced similar outcomes with less
toxicity,12 this regimen was adopted in clinical
practice and in this trial. More than 85% of pa
tients in this trial who were in the chemotherapyonly group received the planned six cycles,
whereas only 63% completed all cycles of treat
ment in GOG 122, as a result of treatment-related
n engl j med 380;24

toxic effects. Full delivery of chemotherapy was
diminished by the addition of radiotherapy, with
only 75% of women completing the four planned
courses in the chemoradiotherapy group. These
results are similar to previous observations in
GOG 184, in which only 80% of patients com
pleted the intended chemotherapy after radio
therapy,11 and may have contributed to the higherthan-anticipated frequency of distant metastases.
The results of our trial could lead to specula
tion that external-beam radiotherapy should be
delivered after completion of chemotherapy. Singleinstitution retrospective studies using a “sand
wich” radiotherapy–chemotherapy approach have
suggested a reasonable side-effect profile and
estimated 5-year overall and distant metastasisfree survival of 77% and 85%, respectively.36,37
Because these results have not been validated
prospectively, they should not be adopted with
out further study. Likewise, substituting vaginal
brachytherapy for external-beam radiotherapy may
be tempting, but because the risk of vaginal recur
rence is low, intracavitary radiotherapy should
be reserved for women who are at high risk for
vaginal relapse. Finally, the short-term and longterm effects of treatment on quality of life should
be considered. Although acute toxic effects were
more common in the chemoradiotherapy group
than in the chemotherapy-only group in our trial,
most were low-grade and reversible on treatment
discontinuation. Chronic toxic effects included
diarrhea, lymphedema, and musculoskeletal events
and were more common with chemoradiother
apy, which affected patient-reported outcomes.
Late second cancers are also a risk.
In summary, in this randomized trial, the
combined regimen of chemotherapy plus radia
tion did not provide a benefit over chemotherapy
alone with respect to relapse-free survival in pa
tients with stage III or IVA endometrial carci
noma. Our data are compatible with the hypoth
esis from previous studies that completion of
chemotherapy is important for the prevention
of distant relapse.
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